Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Odetola, Oluwatobi; Ma, Shuo

Odetola, Oluwatobi; Ma, Shuo.

Affiliation

Odetola O; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 805, Chicago, IL, 60611, USA. Oluwatobi.odetola@northwestern.edu.
Ma S; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 805, Chicago, IL, 60611, USA.

Curr Hematol Malig Rep ; 18(5): 130-143, 2023 10.

Article in En | MEDLINE | ID: mdl-37278884

Subject(s)

Antineoplastic Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Humans; Aged; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell/genetics; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Antineoplastic Agents/therapeutic use

Key words

BTK inhibitor; Monoclonal antibody; Relapsed CLL; Targeted therapy; Venetoclax

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Agents Limits: Aged / Humans Language: En Journal: Curr Hematol Malig Rep Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2023 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google